Late treatment with autologous expanded regulatory T-cell therapy after alemtuzumab induction is safe and facilitates immunosuppression minimization in living donor renal transplantation

অনুরূপ উপাদানগুলি

• Transplantation Without Overimmunosuppression (TWO) study protocol: a phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients
  অনুযায়ী: Brook, MO, অন্যান্য
  প্রকাশিত: (2022)
• Transplantation Without Overimmunosuppression (TWO) study protocol: a phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients
  অনুযায়ী: Susan Dutton, অন্যান্য
  প্রকাশিত: (2022-04-01)
• Th17 cells in alemtuzumab-treated patients: the effect of long-term maintenance immunosuppressive therapy.
  অনুযায়ী: Hester, J, অন্যান্য
  প্রকাশিত: (2011)
• Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation.
  অনুযায়ী: Muthusamy, A, অন্যান্য
  প্রকাশিত: (2008)
• Steroid-free immunosuppression in pancreas transplantation using Alemtuzumab induction
  অনুযায়ী: Muthusamy, A, অন্যান্য
  প্রকাশিত: (2007)